CN116897054A - 抗her2免疫缀合物及其用途 - Google Patents

抗her2免疫缀合物及其用途 Download PDF

Info

Publication number
CN116897054A
CN116897054A CN202180092533.5A CN202180092533A CN116897054A CN 116897054 A CN116897054 A CN 116897054A CN 202180092533 A CN202180092533 A CN 202180092533A CN 116897054 A CN116897054 A CN 116897054A
Authority
CN
China
Prior art keywords
alkyldiyl
immunoconjugate
cancer
group
peg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202180092533.5A
Other languages
English (en)
Chinese (zh)
Inventor
S·E·阿克曼
M·N·阿隆索
R·顾迪尔卡
A·李
B·萨菲纳
M·周
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bolt Biotherapeutics Inc
Original Assignee
Bolt Biotherapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bolt Biotherapeutics Inc filed Critical Bolt Biotherapeutics Inc
Publication of CN116897054A publication Critical patent/CN116897054A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202180092533.5A 2020-12-11 2021-12-10 抗her2免疫缀合物及其用途 Pending CN116897054A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063124421P 2020-12-11 2020-12-11
US63/124,421 2020-12-11
PCT/US2021/062833 WO2022125915A1 (en) 2020-12-11 2021-12-10 Anti-her2 immunoconjugates, and uses thereof

Publications (1)

Publication Number Publication Date
CN116897054A true CN116897054A (zh) 2023-10-17

Family

ID=79425413

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202180092533.5A Pending CN116897054A (zh) 2020-12-11 2021-12-10 抗her2免疫缀合物及其用途

Country Status (6)

Country Link
US (1) US20240042050A1 (https=)
EP (1) EP4259211A1 (https=)
JP (1) JP2023552791A (https=)
CN (1) CN116897054A (https=)
CA (1) CA3200320A1 (https=)
WO (1) WO2022125915A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023154318A1 (en) * 2022-02-09 2023-08-17 Bolt Biotherapeutics, Inc. Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof
WO2024173387A1 (en) 2023-02-14 2024-08-22 Bolt Biotherapeutics, Inc. Aza-benzazepine immunoconjugates, and uses thereof

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988007089A1 (en) 1987-03-18 1988-09-22 Medical Research Council Altered antibodies
WO1989006692A1 (en) 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6800738B1 (en) 1991-06-14 2004-10-05 Genentech, Inc. Method for making humanized antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
PT1308456E (pt) 1998-05-06 2007-12-03 Genentech Inc Purificação de anticorpos por cromatografia de permuta iónica
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
CA2399940A1 (en) 2000-04-13 2001-10-25 The Rockefeller University Enhancement of antibody-mediated immune responses
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
WO2006073921A2 (en) 2004-12-30 2006-07-13 The Rockefeller University Compositions and methods for enhanced dendritic cell maturation and function
US20080286819A1 (en) 2005-11-07 2008-11-20 Ravetch Jeffrey V Reagents, Methods and Systems for Selecting a Cytotoxic Antibody or Variant Thereof
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
JP5889912B2 (ja) 2010-11-17 2016-03-22 ジェネンテック， インコーポレイテッド アラニニルメイタンシノール抗体コンジュゲート
MY189836A (en) 2014-11-21 2022-03-11 Bristol Myers Squibb Co Antibodies against cd73 and uses thereof
AU2019337654A1 (en) * 2018-09-12 2021-04-08 Silverback Therapeutics, Inc. Substituted benzazepine compounds, conjugates, and uses thereof
WO2020252254A1 (en) * 2019-06-13 2020-12-17 Bolt Biotherapeutics, Inc. Macromolecule-supported aminobenzazepine compounds
AU2020291014B2 (en) * 2019-06-13 2025-06-05 Bolt Biotherapeutics, Inc. Aminobenzazepine compounds, immunoconjugates, and uses thereof
CN115996756A (zh) * 2020-05-08 2023-04-21 博尔特生物治疗药物有限公司 弹性蛋白酶底物肽连接子免疫缀合物及其用途

Also Published As

Publication number Publication date
WO2022125915A1 (en) 2022-06-16
US20240042050A1 (en) 2024-02-08
CA3200320A1 (en) 2022-06-16
EP4259211A1 (en) 2023-10-18
JP2023552791A (ja) 2023-12-19

Similar Documents

Publication Publication Date Title
CN115996756A (zh) 弹性蛋白酶底物肽连接子免疫缀合物及其用途
WO2021067242A1 (en) Amide-linked, aminobenzazepine immunoconjugates, and uses thereof
CN119212730A (zh) 包含通过与一种或多种8-Het-2-氨基苯并氮杂䓬衍生物缀合连接的抗CEA抗体的用于治疗癌症的免疫缀合物
JP2022546110A (ja) アミノキノリン化合物、免疫複合体、及びそれらの使用
CN117769439A (zh) 2-氨基-4-甲酰胺-苯并氮杂卓免疫缀合物及其用途
CN116744978A (zh) 抗her2免疫缀合物及其用途
CN116897054A (zh) 抗her2免疫缀合物及其用途
WO2023154318A1 (en) Anti-tr0p2, aminobenzazepine immunoconjugates, and uses thereof
CN116635084A (zh) 抗cea免疫缀合物和其用途
CN116723866A (zh) 抗pd-l1免疫缀合物和其用途
KR20240139086A (ko) 항체-접합된 8-설포닐-벤자제핀 화합물 및 이의 용도
CN117940168A (zh) 2-氨基-4-甲酰胺-苯并氮杂䓬免疫缀合物及其用途
CN118843480A (zh) 高分子负载的8-磺酰基-苯并氮杂䓬化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination